Clear Scientific received continued support to further test novel atropine injectable
- Clear Scientific
- Aug 1, 2021
- 1 min read
Updated: Mar 7, 2022
Cambridge, Massachusetts | August 2021
Clear Scientific recently received continued funding and support to further test and develop our novel atropine injectable therapeutic. Atropine is a previously FDA-approved treatment for acute nerve agent poisoning. Our current formulation demonstrates improved shelf-life stability as well as enhanced treatment benefits against nerve agents. The Phase II extension support enables CSInc to continue testing the efficacy of our improved therapeutic as we progress toward FDA submission of our medicinal formulation.
The continued funding for Clear Scientific's novel atropine injectable, especially with its improved shelf-life stability and enhanced treatment benefits, is a significant advancement. This kind of robust development is crucial for life-saving therapeutics, ensuring they are effective and readily available when emergencies strike. This ongoing research underscores the critical importance of rigorous testing and development for effective medical interventions. It also brings to mind the broader landscape of diagnostic needs across various health challenges. For individuals facing different health battles, such as those related to substance use, having access to comprehensive addiction testing can be just as life-changing.